Composition comprising avermectin compounds without solid fatty substances
Composition comprising avermectin compounds without solid fatty substances The invention relates to a dermatological or pharmaceutical composition comprising at least one aqueous phase and at least one active phase comprising at least one active compound chosen from avermectin compounds and at least one solvent and/or propenetrating agent of avermectin compounds, where the composition comprises less than 3 % by weight of solid fatty substances at room temperature and at atmospheric pressure, relative to the total weight of the composition. The invention relates also to the composition for use in the treatment of rosacea, of common acne, of seborrheic dermatitis, of perioral dermatitis, of acneiform rashes, of transient acantholytic dermatosis, of acne necrotica miliaris and of atopic dermatitis, and preferably for use in the treatment of rosacea. Finally, the invention relates to a method for preparing the composition.
1. A dermatological or pharmaceutical composition, comprising:
(a) 70 to 95% by weight, relative to the total weight of the composition, of at least one aqueous phase; and
(b) 5 to 30% by weight, relative to the total weight of the composition, of at least one active phase comprising at least one avermectin compound and at least one solvent and/or propenetrating agent of avermectin compounds,
wherein the composition comprises less than 3% by weight of solid fatty substances at room temperature and at atmospheric pressure, relative to the total weight of the composition.
2. The dermatological or pharmaceutical composition according to claim 1 , wherein solid fatty substances are selected from fatty acids, fatty alcohols, waxes, gums, and mixtures thereof.
3. The dermatological or pharmaceutical composition according to claim 1 , wherein the composition does not comprise stearyl alcohol and cetyl alcohol.
4. The dermatological or pharmaceutical composition according to claim 3 , wherein the composition does not comprise any solid fatty substance.
5. The dermatological or pharmaceutical composition according to claim 1 , wherein the avermectin compound is selected from ivermectin, invermectin, avermectin, abamectin, doramectin, eprinomectin and selamectin.
6. The dermatological or pharmaceutical composition according to claim 5 , wherein the avermectin compound is ivermectin.
7. The dermatological or pharmaceutical composition according to claim 1 , comprising from 0.01 to 10% by weight, of the at least one avermectin compound, relative to the total weight of the composition.
8. The dermatological or pharmaceutical composition according to claim 7 , comprising from 0.1 to 5% by weight, of the at least one avermectin compound, relative to the total weight of the composition.
9. The dermatological or pharmaceutical composition according to claim 1 , wherein solvents and propenetrating agents of avermectin compounds are selected from propylene glycol, ethanol, isopropanol, butanol, N-methyl-2-pyrrolidone, dimethylsulfoxyde, polysorbate 80, poloxamer 124, phenoxyethanol, oleyl alcohol, isostearic acid, diisopropyl adipate, polypropylene glycol-15 stearyl ether (“PPG-15 stearyl ether”), octyl dodecanol, ethyl oleate, C12-C15 alkyl benzoate and mixtures thereof.
10. The dermatological or pharmaceutical composition according to claim 1 , comprising 1 to 10% by weight of solvents and propenetrating agents of avermectin compounds, relative to the total weight of the composition.
11. The dermatological or pharmaceutical composition according to claim 1 , comprising 3 to 7% by weight of solvents and propenetrating agents of avermectin compounds, relative to the total weight of the composition.
12. The dermatological or pharmaceutical composition according to claim 1 , further comprising one or more surfactants.
13. The dermatological or pharmaceutical composition as defined in claim 12 , wherein the surfactants are selected from non-ionic surfactants.
14. The dermatological or pharmaceutical composition as defined in claim 12 , wherein the surfactants are selected from polyoxyethylenated fatty alcohol ethers, sorbitan esters, and mixtures thereof.
15. A method of treating rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acneiform rashes, transient acantholytic dermatosis, acne necrotica miliaris and/or atopic dermatitis, comprising administering the dermatological or pharmaceutical composition according to claim 1 .
16. The method according to claim 15 , for the treatment of rosacea.
17. The method according to claim 16 , wherein the dermatological or pharmaceutical composition is administered topically.
18. A method for preparing the composition according to claim 1 , comprising:
(a) mixing the at least one avermectin compound with the other components of the active phase, wherein the active phase is present at a concentration of 5 to 30% by weight, relative to the total weight of the composition;
(b) mixing the constituents of the aqueous phase to homogeneity, wherein the aqueous phase is present at a concentration of 70 to 95% by weight, relative to the total weight of the composition; and then
(c) incorporating the active phase into the aqueous phase so as to form the composition.
19. The composition of claim 1 , wherein the viscosity of the composition is from about 1000 cP to 10000 cP at room temperature.
20. The composition of claim 1 , wherein the viscosity of the composition is from about 1500 cP to 5000 cP at room temperature.
21. The composition of claim 1 , wherein the yield stress of the composition is from about 5 Pa to 50 Pa at room temperature.
22. The composition of claim 1 , wherein the yield stress of the composition is from about 10 Pa to 20 Pa at room temperature.